期刊
FRONTIERS IN ONCOLOGY
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2023.1205720
关键词
rituximab; steroid-refractory pancreatitis; immune-related adverse event; atezolizumab; immune checkpoint inhibitors
类别
The use of immune checkpoint inhibitors can cause immune-related adverse events, including pancreatitis. Steroids are commonly used to treat pancreatitis induced by immune checkpoint inhibitors. However, little is known about the management of steroid-refractory cases. This case presentation suggests that rituximab may be an effective treatment option for such cases.
The use of immune checkpoint inhibitors (ICIs) for treating several types of cancer is increasing, but they may be associated with immune-related adverse events (irAEs). Pancreatitis is a rare irAE, mostly responsive to steroid treatment. There are no published data on the management of steroid-refractory ICI-induced pancreatitis. Rituximab has shown efficacy in the setting of relapsing non-ICI-induced autoimmune pancreatitis. However, its use has not been tested for treating immunotherapy-related pancreatitis. Here, we present the case of a patient with steroid-refractory immune-related pancreatitis successfully treated with rituximab as a potential strategy for irAE management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据